Skip to main content Back to Top
Advertisement

11/11/2019

Cefotaxime Sodium Injection

Products Affected - Description

    • Claforan injection, Baxter, 1 gram/50 mL, frozen premixed bag, 24 count, NDC 00039-0038-05 - discontinued
    • Claforan injection, Baxter, 2 gram/50 mL, frozen premixed bag, 24 count, NDC 00039-0039-05 - discontinued
    • Cefotaxime Sodium powder for solution for injection, Hikma, 1 gram, vial, 25 count, NDC 00143-9931-25
    • Cefotaxime Sodium powder for solution for injection, Hikma, 10 gram, vial, 1 count, NDC 00143-9935-01
    • Cefotaxime Sodium powder for solution for injection, Hikma, 2 gram, vial, 25 count, NDC 00143-9933-25
    • Cefotaxime Sodium powder for solution for injection, Hikma, 500 mg, vial, 10 count, NDC 00143-9930-10

Reason for the Shortage

    • Hospira has discontinued Claforan. Sanofi-Aventis manufactured Claforan for Hospira and is no longer making the product.
    • Baxter discontinued Claforan in late-2015.
    • Hikma is not currently marketing cefotaxime injection.

Estimated Resupply Dates

    • Apollo Pharmaceuticals is temporarily importing cefotaxime 1 gram and 2 gram vials.

Alternative Agents & Management

    • FDA is allowing temporary importation of cefotaxime 1 gram and 2 gram vials from Apollo Pharmaceuticals and its distributor FFF Enterprises. The cefotaxime is supplied by SteriMax from Canada. Customers can call FFP Enterprises at 1-800-843-7477 to place orders. More information can be found at https://www.fda.gov/media/130296/download.

Updated

Updated November 11, 2019 by Michelle Wheeler, PharmD, Drug Information Specialist. Created July 31, 2013 by Michelle Wheeler, PharmD, Drug Information Specialist. © 2019, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Vizient to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Vizient, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Vizient, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Vizient, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins